Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ziaul Karim has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Disruption of cellular timekeeping in cancer: links between circadian clocks, metabolism, and tumor progression

    by Ziaul Karim, Lahanya Guha, Priya Manna, Anjan Gowda Bh, Ajay Kumar Gupta, Khalid Rehman Hakeem

    Disruption of cellular timekeeping systems is a key driver of cancer cell development and progression. The circadian clock is a 24-hour regulatory system that relies on core clock genes - CLOCK, BMAL1, PER, and CRY. Maintaining cellular homeostasis is essential, as it regulates processes such as the cell cycle, metabolism, DNA repair, and apoptosis. Disruption of Circadian rhythms is common in cancer, altering gene expression and causing the mis-timing of cellular events. This disturbance stimulates excessive growth, genetic instability, and resistance to cell death. Circadian rhythms and tumour growth disruption are linked by metabolic reprogramming. Cancer cells show enhanced glycolysis, lipid production, and modified mitochondrial activity, all of which are typically regulated by the circadian clock. The irregular functioning of clock genes leads to metabolic changes that facilitate tumor development and survival. This also enhances metastatic progression by regulating the tumor’s angiogenesis, inflammation, and immunological responses. Recent studies posit the clinical relevance of targeting circadian circuits in cancer therapy. Chronotherapy is the practice of administering therapies in accordance with the body’s biological rhythms. It is expected to increase the treatment’s therapeutic efficacy while decreasing toxicity significantly. This review underscores the complex molecular connections between circadian clock disruption, metabolic changes, and tumor progression. It highlights the potential of incorporating circadian biology into cancer research to advance biomarker discovery, precision oncology, and the creation of novel therapeutic strategies. Graphical abstract

  • Open Access

    Oral Delivery of a GI-Stable Apigenin–Cyclodextrin Complex via Pectin-Coated Nanoliposomes In Situ Gel: A DoE-Optimized Targeted Colon Cancer Therapy by Modulating Gut Drug Sensitivity

    by Moumita Dhara, Kusum Devi Vemula, Ziaul Karim, Anoop Narayanan Vadakkepushpakath, Tanvi Shetty, Anushree Prakasha Munchinamane

    This study emphasizes overcoming the challenges of targeted drug delivery in colon cancer therapy by developing gastrointestinal (GI) stable, pectin-coated nanoliposomes for the oral delivery of Apigenin-Cyclodextrin Complex as an in situ gel formation. Initially, the formulation was strategically designed using design expert software for formulation optimization. FTIR and XRD studies were conducted to ensure physical compatibility and to confirm the encapsulation of apigenin within the formulation. In process optimization, among all seventeen formulations run tested, PNL (Api-Cy)-13 was identified for the highest drug loading, favourable size dimension of particle with zeta potential, and spherical external morphology through SEM analysis. The metered drug release during an in vitro study for PNL (Api-Cy)-13 was remarkably high (more than 75% of drug availability in the colonic environment, precisely in contrast to only 20% in the gastric phase in a sustained release manner), focused on colon drug targeting as an in situ gel. Furthermore, apigenin release from PNL (Api-Cy)-13 in an ex vivo chick ileum permeability study was observed both in the absence and presence of 1% vancomycin. An incremental apigenin release in the absence of the antibiotic (1% vancomycin) indicated gut microbial-associated and pectinase-mediated drug release. Here, pectin degradation materializes by the colonic microbial environment, which facilitates desirable incremental colonic drug permeation. Finally, an in vitro MTT assay and a competitive flowcytometric cell uptake study with PNL (Api-Cy)-13 using HCT-116 cells proved significant superiority in cytotoxicity profile for apigenin when delivered as an optimized coated nanoliposome in comparison to free apigenin or other non-modified nano-formulation. Also, the inhibition of the cell efflux process was validated by Multidrug Resistance 1 (MDR1) gene regulation. These observations establish an undoubted promise for the novel biopolymer, pectin-based apigenin-cyclodextrin nanoliposomes as targeted therapy in colon cancer with significant in vivo pharmacokinetics and safety profile.